Please use this identifier to cite or link to this item:
Title: Effects of biperiden on the treatment of cocaine/crack addiction: A randomised, double-blind, placebo-controlled trial
Authors: Junqueira Dieckmann, Luiz Henrique [UNIFESP]
Ramos, Anna Carolina [UNIFESP]
Silva, Eroy Aparecida [UNIFESP]
Justo, Luis Pereira [UNIFESP]
Sabioni, Pamela [UNIFESP]
Frade, Iracema Francisco [UNIFESP]
Souza, Altay Lino de [UNIFESP]
Fernandes Galduroz, Jose Carlos [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Keywords: Cocaine
Cholinergic antagonist
Issue Date: 1-Aug-2014
Publisher: Elsevier B.V.
Citation: European Neuropsychopharmacology. Amsterdam: Elsevier B.V., v. 24, n. 8, p. 1196-1202, 2014.
Abstract: Cocaine use affects approximately 13.4 million people, or 0.3% of the world's population between 15 and 64 years of age. Several authors have described drug addiction as a disease of the brain reward system. Given that the cholinergic system impacts reward mechanisms and drug self-administration, acetylcholine (ACh) might play an important role in the cocaine addiction process. We evaluated the efficacy of biperiden (a cholinergic antagonist) in reducing craving and the amount used, and in increasing compliance with treatment for cocaine/crack addiction. It was a study double-blind, randomised, placebo-controlled, 8-week trial of 111 cocaine or crack addicted male patients between 18 and 50 years old. Two groups were compared: placebo (n=55) or biperiden (n=56) combined with weekly sessions of brief group cognitive-behavioural therapy. the efficacy of treatment was evaluated according to the patients' compliance and several instruments: the Minnesota Cocaine Craving Scale, the Beck Depression and Anxiety Scales and a questionnaire assessing the amount of drug used. All of the patients attended weekly sessions for two months. We analysed the data considering the patients' intention to treat based on our last observation. of the 56 patients in the biperiden group, 24 completed the treatment (42.8%) compared with only 11 patients in the placebo group (20%), which was a significant difference (p=0.009). Compliance with treatment was 118% higher in the biperiden group, which was also the group that presented a statistically significant reduction in the amount of cocaine/crack use (p<0.001). There was statistically significant difference between the craving score in the biperiden group. Pharmacological blockade of the cholinergic system with biperiden is a promising alternative to treat cocaine/crack addiction, helping patients to reduce the amount used and improving compliance with psychotherapy treatment. (C) 2014 Elsevier B.V. and ECNP. All rights reserved.
ISSN: 0924-977X
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.